Arcellx Inc (ACLX)

Name: Arcellx Inc (ACLX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Arcellx Inc (ACLX)

Stock Card

$115.07

$0.00 (0.00%)

As on 15-May-2026 16:00EDT

Market cap

$6,732 Mln

Revenue (TTM)

$22 Mln

P/E Ratio

P/B Ratio

16.7

Div. Yield

0 %

Arcellx Inc (ACLX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 115.05 High: 115.05

52 Week Range

Low: 56.58 High: 115.13

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-6.5
Debt to Equity

0.2
Book Value

$7.1
EPS

$-4.1
Face value

--
Shares outstanding

58,506,348

6 Years Aggregate

CFO

$-0.26 Mln

EBITDA

$-387.89 Mln

Net Profit

$-370.78 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Arcellx Inc (ACLX)	76.5	0.2	68.0	95.0	40.4	--	--
BSE Sensex^*	-9.0	-1.3	3.1	-3.4	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 15-May-2026 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023
Arcellx Inc (ACLX)	-15.0	37.8	79.1
S&P Small-Cap 600	4.0	7.0	13.9
BSE Sensex	9.1	8.1	18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Arcellx Inc (ACLX)	115.1	6,732.3	22.3	-228.9	-918.3	-53.4	--	16.7
GalectoÂ Inc (GLTO)	24.5	1,728.3	0.0	-235.1	--	-91	--	163.8
OpGen (OPGN)	0.3	251.2	5.2	12.0	-156.5	162.5	137.5	0.0
Terns Pharmaceuticals (TERN)	53.0	6,116.9	0.0	-96.2	--	-14.2	--	6.1

Shareholding Pattern

View Details

About Arcellx Inc (ACLX)

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel,... which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. As of April 28, 2026, Arcellx, Inc. operates as a subsidiary of Gilead Sciences, Inc. Read more

Chairman of the Board, CEO & President

Mr. Rami Elghandour
Chairman of the Board, CEO & President

Mr. Rami Elghandour
Headquarters

Redwood City, CA
Website

https://www.arcellx.com

FAQs for Arcellx Inc (ACLX)

What is the current share price of Arcellx Inc (ACLX) Today?

The share price of Arcellx Inc (ACLX) is $115.07 (NASDAQ) as of 15-May-2026 16:00 EDT. Arcellx Inc (ACLX) has given a return of 40.37% in the last 3 years.